Table 2.
Probabilities of failure and persistence in induction phase by treatment group
| IFX (n = 80) | ADA (n = 53) | Total (n = 133) | p value* | |
|---|---|---|---|---|
| Discontinuation, n (%) | ||||
| No | 63 (78.8%) | 47 (88.7%) | 110 (82.7%) | 0.14 |
| Yes | 17 (21.3%) | 6 (11.3%) | 23 (17.3%) | |
| Switch, n (%) | ||||
| No | 77 (96.3%) | 53 (100.0%) | 130 (97.7%) | 0.28 |
| Yes | 3 (3.8%) | 0 | 3 (2.3%) | |
| Persistence, n (%) | ||||
| No | 20 (25.0%) | 6 (11.3%) | 26 (19.6%) | 0.051 |
| Yes | 60 (75.0%) | 47 (88.7%) | 107 (80.5%) | |
ADA adalimumab, IFX infliximab
* Continuous variables were compared using the student test or the Wilcoxon test; categorical variables were compared using the Chi-square test or the Fisher’s exact test